Plasma-Derived Products
This line will be dedicated to the manufacturing of medicinal products derived from human plasma, such as albumin, immunoglobulins, and coagulation factors. These products are essential for the treatment of immune deficiencies, hemophilia, autoimmune diseases, and for use in intensive care. They address critical public health needs in Algeria and aim to reduce reliance on imports.
Monoclonal Antibodies Products
The second line will focus on the production of biosimilar monoclonal antibodies, used in the treatment of serious diseases such as cancers (breast, colon, lung), chronic inflammatory diseases (rheumatoid arthritis, Crohn’s disease), and certain autoimmune conditions. This line will provide access to innovative, high-quality treatments manufactured locally.
Recombinant Hormonal Products
The third line will be dedicated to the production of recombinant hormonal proteins, particularly gonadotropins (FSH, LH, hCG), used in the treatment of both female and male infertility. These products are essential in assisted reproductive technology (ART) protocols and represent a strategic area to meet growing demand in Algeria and the region.